A method for detecting free cortisol in urine using liquid chromatography tandem mass spectrometry

By adding cortisol isotope internal standard solution to simplify pretreatment and directly performing liquid chromatography detection, the problem of complex and costly pretreatment of liquid chromatography tandem mass spectrometry in urine free cortisol detection is solved, and the problem of filtration tandem mass spectrometry is solved, achieving Efficient and accurate large-scale detection of urinary free cortisol in urine.

CN116046935BActive Publication Date: 2024-11-15TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211678945.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-26
Publication Date
2024-11-15
Estimated Expiration
2042-12-26

AI Technical Summary

Technical Problem

The existing liquid chromatography tandem mass spectrometry has problems such as cumbersome pretreatment steps, large sample usage, long time, high reagent and consumables and environmental pollution in the detection of urinary free cortisol. The standard curve is difficult to accurately reflect the real sample situation, which makes it difficult to Large-scale application.

Method used

The working solution of cortisol isotopes is mixed with the urine sample and centrifuged, and liquid chromatography is directly carried out to draw standard curves through mass spectrometry, simplify the pre-treatment steps, reduce background noise, improve signal-to-noise ratio, and achieve large-scale detection.

Benefits of technology

Simplified sample pretreatment, reduced sample dosage and reagent consumables, reduced costs, improved detection efficiency and accuracy, and is suitable for high-throughput detection needs in clinical laboratories.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116046935B_ABST
    Figure CN116046935B_ABST
Patent Text Reader

Abstract

The present application relates to the field of biological sample detection, and in particular to a method for detecting free cortisol in urine by using liquid chromatography-tandem mass spectrometry; the method comprises: mixing a calibration solution and a urine sample to be tested with a cortisol isotope internal standard working solution respectively, then centrifuging, taking the supernatant, and obtaining a calibration supernatant and a sample supernatant to be tested respectively; detecting the calibration supernatant by using liquid chromatography-tandem mass spectrometry, and drawing a standard curve; detecting the supernatant of the sample to be tested by using liquid chromatography-tandem mass spectrometry, and obtaining the content of free cortisol in the urine sample to be tested according to the standard curve; wherein the solute of the cortisol isotope internal standard working solution comprises cortisol-d and / or cortisol-13C; the method has simple pre-treatment, small sample consumption, and low reagent and consumable cost, and is conducive to realizing large-scale liquid chromatography-tandem mass spectrometry detection of free cortisol in urine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biological sample detection, and in particular to a method for detecting free cortisol in urine using liquid chromatography-tandem mass spectrometry. Background Art

[0002] Cortisol is a steroid hormone that plays a key role in glucose metabolism, maintaining vascular tone, immune regulation, and stress response, and is mainly regulated by hypothalamic-pituitary feedback. Urinary free cortisol (UFC) is a sensitive indicator of various adrenal cortical dysfunctions, especially hypercortisolism (Cushing's syndrome). At the same time, the determination of 24-hour UFC is recommended by the guidelines as a first-line test for Cushing's syndrome screening.

[0003] Traditional detection methods for UFC include radioimmunoassay, luminescence immunoassay, liquid chromatography-ultraviolet detection, and gas chromatography-mass spectrometry. These methods all have the disadvantages of complex pretreatment processes and cumbersome steps. Among them, the radioimmunoassay and luminescence immunoassay commonly used in clinical practice are prone to cross-reactions and have limited detection sensitivity. In recent years, liquid chromatography tandem mass spectrometry (LC-MS / MS) has been increasingly used for the detection of UFC. This method has the advantages of high sensitivity, good specificity, high throughput, and short detection time. In liquid chromatography tandem mass spectrometry, in order to remove the interference of sample protein, the sample usually needs to be pretreated before detection. The currently reported sample pretreatment methods are mostly protein precipitation, liquid-liquid extraction (LLE) or solid phase extraction (SPE). However, these pretreatment methods are not only cumbersome in operation steps and large in sample volume, but also time-consuming, high in reagent and consumable costs and environmental pollution. In addition, the calibration solution used to draw the standard curve mostly uses 4% (w / w) bovine serum albumin solution or pure solution, which is quite different from the real human sample matrix, and thus cannot accurately reflect the actual situation of the sample to be tested, making it difficult to apply this method to the detection of urine free cortisol on a large scale. Therefore, how to provide a large-scale method for detecting urine free cortisol using liquid chromatography tandem mass spectrometry is a technical problem that urgently needs to be solved. Summary of the invention

[0004] The present application provides a method for detecting free cortisol in urine using liquid chromatography tandem mass spectrometry to solve the technical problem in the prior art that liquid chromatography tandem mass spectrometry is difficult to be applied on a large scale to detect free cortisol in urine.

[0005] In a first aspect, the present application provides a method for detecting free cortisol in urine using liquid chromatography tandem mass spectrometry, the method comprising:

[0006] The calibration solution and the urine sample to be tested are respectively mixed with the cortisol isotope internal standard working solution, and then centrifuged to obtain the supernatant to obtain the calibration supernatant and the sample supernatant;

[0007] Directly detecting the obtained calibration sample supernatant by liquid chromatography-tandem mass spectrometry, and drawing a standard curve;

[0008] Using liquid chromatography tandem mass spectrometry to detect the supernatant of the sample to be tested, and obtaining the content of free cortisol in the urine sample to be tested according to the standard curve;

[0009] Wherein, the cortisol isotope internal standard working solution comprises a cortisol isotope internal standard solute and a cortisol isotope internal standard solvent;

[0010] The cortisol isotope internal standard solute includes cortisol-d and / or cortisol-13C;

[0011] The cortisol isotope internal standard solvent includes methanol and / or water.

[0012] Optionally, the method further includes:

[0013] The ex vivo urine samples were subjected to solid phase extraction until cortisol was free to obtain blank urine matrix;

[0014] A cortisol stock solution is prepared and first diluted, and then a second dilution is performed with a blank urine matrix to obtain a calibrator solution;

[0015] Wherein, the concentration of the calibration solution is 0.625ng / mL to 500ng / mL.

[0016] Optionally, the dilution solvent of the first dilution is a mixture of methanol and water, wherein the volume ratio of the methanol to the water is 1:3 to 3:1.

[0017] Optionally, the second dilution includes performing the second dilution in a stepwise dilution manner, and the endpoint solution concentration of the second dilution is 0.625 ng / mL to 500 ng / mL.

[0018] Optionally, the ratio of the volume of the urine sample to be tested to the volume of the cortisol isotope internal standard working solution is 1:2 to 1:6.

[0019] Optionally, the cortisol isotope internal standard solvent includes a mixture of methanol and water, wherein the volume ratio of the methanol to the water is 1:3 to 3:1.

[0020] Optionally, the sampling volume of the urine sample to be tested is 10 μL to 100 μL.

[0021] Optionally, the centrifugal rotation speed is ≥12000 rpm, and the centrifugal time is 2 min to 10 min.

[0022] Optionally, the liquid chromatography tandem mass spectrometry includes a liquid chromatography, the chromatographic column of the liquid chromatography is a reverse phase chromatography column, the column temperature of the liquid chromatography is 30°C to 50°C, the injection volume of the liquid chromatography is 2μL to 10μL, and the flow rate of the liquid chromatography is 0.3mL / min to 0.5mL / min; the liquid chromatography uses a gradient elution method for chromatographic separation, and the gradient elution mobile phase A includes an aqueous solution with a mass fraction of 0% to 0.1% formic acid, and the gradient elution mobile phase B includes a methanol solution with a mass fraction of 0% to 0.1% formic acid.

[0023] Optionally, the liquid chromatography tandem mass spectrometry comprises a mass spectrometer;

[0024] The mass spectrometer includes an electrospray ion source, the working mode of the mass spectrometer is a negative ion mode, and the ion source parameters of the mass spectrometer include curtain gas: 30psi±5psi, collision gas: 9.0psi±0.2psi, ion source voltage: -4500V±10V, ion source temperature: 500℃±10℃, atomizing gas: 40psi±5psi, auxiliary heating gas: 50psi±5psi. The above technical solution provided in the embodiment of the present application has the following advantages compared with the prior art:

[0025] A method for detecting free cortisol in urine by liquid chromatography tandem mass spectrometry provided in an embodiment of the present application is different from the traditional liquid chromatography tandem mass spectrometry detection of cortisol. The present method only adds a cortisol isotope internal standard working solution to the urine sample to be tested, centrifuges after mixing, obtains a supernatant, separates it by liquid chromatography, and detects it by mass spectrometry, wherein the isotope internal standard solution contains a certain proportion of organic solvent, which can precipitate a small amount of protein in urine, and realizes that solid phase extraction (SPE) in the prior art is not required; and the isotope internal standard solution contains a certain proportion of water, which can make the supernatant to be tested closer to the composition and polarity of the chromatographic mobile phase, which is conducive to reducing the influence of background chemical noise and improving the signal-to-noise ratio. Since the method simplifies the pre-treatment of the sample, the pre-treatment of the sample is simple, fast, the sample dosage is small, and the reagent consumables cost is low, and the pre-treatment operation of the sample to be tested and the isotope internal standard working solution mixed and centrifuged to be detected on the machine is conducive to realizing large-scale liquid chromatography tandem mass spectrometry detection of free cortisol in urine, so by adopting this method, large-scale liquid chromatography tandem mass spectrometry detection of free cortisol in urine can be realized. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present application and, together with the description, serve to explain the principles of the present application.

[0027] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0028] Figure 1 A schematic diagram of a process for a method provided in an embodiment of the present application;

[0029] Figure 2 A detailed flowchart of the method provided in the embodiment of the present application;

[0030] Figure 3 A chromatogram of the calibration solution provided in the examples of the present application;

[0031] Figure 4 A chromatogram of a urine sample to be tested provided in an embodiment of the present application;

[0032] Figure 5 This is a matrix effect diagram provided in the examples of this application. DETAILED DESCRIPTION

[0033] In order to make the purpose, technical solution and advantages of the embodiments of the present application clearer, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0034] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in this application can be purchased from the market or prepared by existing methods.

[0035] Since blood contains proteins, cortisol easily forms a bound state with proteins, and only a small part exists in a free state and is excreted into urine. Therefore, urine cortisol needs to be pre-treated before liquid chromatography-tandem mass spectrometry detection to remove interfering substances in the matrix for quantitative determination. Liquid-liquid extraction or solid phase extraction methods are usually used. Liquid-liquid extraction requires the addition of organic solvents to extract the analytes in the aqueous phase, and then the organic phase layer is taken for drying and concentration, and then re-dissolved and loaded on the machine. The whole process is not only complicated to operate, but also uses toxic organic solvents such as n-hexane, ethyl acetate, and chloroform. Solid phase extraction requires multiple steps such as column equilibration, sample loading, elution, elution, nitrogen blowing, and re-dissolution. The whole process is not only very cumbersome and time-consuming, but also requires comparison of multiple solvents during condition optimization, which pollutes the environment. Moreover, the extraction columns are disposable, and the cost of reagents and consumables is high. In addition, due to too many operating steps, there is a loss of analytes in each step, so the amount of sample required will also increase accordingly. The pretreatment methods reported in the currently published patents or literature are mostly protein precipitation, liquid-liquid extraction (LLE) or solid phase extraction (SPE), such as CN 201610220199.8: "Method and kit for detecting cortisol in saliva by high-performance liquid chromatography tandem mass spectrometry" The sample pretreatment includes mixing 500 μL of saliva sample with internal standard solution, adding a mixture of ethyl acetate and n-hexane for liquid-liquid extraction, and then blowing dry with nitrogen for re-dissolution. The whole process takes at least 21 minutes (excluding nitrogen blowing); CN202011000429.2: "Liquid chromatography tandem mass spectrometry detection method for glucocorticoids in biological fluids" The sample pretreatment includes protein precipitation of 100-500 μL biological fluid samples and then centrifugation, taking the supernatant for solid phase extraction, collecting the eluate and blowing dry with nitrogen, and then re-dissolving and loading on the machine. The whole process takes at least 7 minutes (excluding nitrogen blowing). These treatment methods are not only cumbersome in operation steps and large in sample consumption, but also time-consuming, high in reagent and consumable costs, and environmental pollution.

[0036] The calibrator solutions used to draw standard curves in currently published patents or literature are mostly prepared with 4% (w / w) bovine serum albumin solution (CN201610220199.8) or pure solution (CN202011000429.2). However, there are significant differences between the simulated human sample matrix and pure solvent and the real human sample matrix, and the matrix effect is also different. It cannot reflect the actual analysis of body fluid samples and is not suitable for routine analysis and testing in clinical laboratories.

[0037] Therefore, the shortcomings of the existing liquid chromatography-tandem mass spectrometry detection method make it impossible to use it for the detection of cortisol on a large scale.

[0038] like Figure 1 As shown, the present application provides a method for detecting free cortisol in urine using liquid chromatography tandem mass spectrometry, the method comprising:

[0039] S1. The calibration solution and the urine sample to be tested are mixed with the cortisol isotope internal standard working solution respectively, and then centrifuged to obtain the supernatant to obtain the calibration supernatant and the sample supernatant respectively;

[0040] S2. Detecting the supernatant of the calibration product by liquid chromatography-tandem mass spectrometry and drawing a standard curve;

[0041] S3. Detecting the supernatant of the sample to be tested by liquid chromatography-tandem mass spectrometry, and obtaining the content of free cortisol in the urine sample to be tested according to the standard curve;

[0042] Wherein, the cortisol isotope internal standard working solution comprises a cortisol isotope internal standard solute and a cortisol isotope internal standard solvent;

[0043] The cortisol isotope internal standard solute includes cortisol-d ((≥3)) and / or cortisol-13C (≥1);

[0044] The cortisol isotope internal standard solvent includes methanol and / or water.

[0045] In the embodiments of the present application, controlling the specific types of solute and solvent of the cortisol isotope internal standard working solution can remove impurity interference and / or improve the signal-to-noise ratio, thereby ensuring that the analyte and its isotope internal standard are detected in the liquid chromatography tandem mass spectrometry.

[0046] The calibrator solution is a solution for calibration obtained by adjusting the volume and / or diluting the cortisol working solution with a certain solvent. The solvent includes a synthetic pure solution matrix or a simulated matrix, and also includes urine from which cortisol has been removed from in vitro urine.

[0047] In some optional embodiments, such as Figure 2 As shown, the method also includes:

[0048] S101. Perform solid phase extraction on the isolated urine sample until no cortisol is present, thereby obtaining a blank urine matrix;

[0049] S102. Prepare a stock solution of cortisol and perform a first dilution, then perform a second dilution with a blank urine matrix to obtain a calibration solution

[0050] Wherein, the concentration of the calibration solution is 0.625ng / mL to 500ng / mL.

[0051] In the embodiment of the present application, the positive effect of controlling the concentration of the calibrator solution to 0.625 ng / mL to 500 ng / mL is that within this concentration range, the concentration gradient of the calibrator solution can be guaranteed to meet expectations and cover the analytical concentration range of the analyte in the clinical sample, ensuring that an accurate quantitative correction equation is obtained by plotting a standard curve graph using calibrators of known concentrations and internal standards, thereby accurately reflecting the cortisol content based on the signal response degree of the urine test sample.

[0052] In some optional embodiments, the dilution solvent of the first dilution is a mixture of methanol and water, wherein the volume ratio of the methanol to the water is 1:3 to 3:1.

[0053] In the embodiment of the present application, the positive effect of controlling the volume ratio of methanol and water to 1:3 to 3:1 is that within the range of this volume ratio, the solute of the cortisol isotope internal standard solution can be ensured to be fully dissolved, while effectively removing a small amount of protein in the urine and reducing the background signal.

[0054] In some optional embodiments, the second dilution includes performing the second dilution in a stepwise dilution manner, and the endpoint solution concentration of the second dilution is 0.625 ng / mL to 500 ng / mL.

[0055] In the embodiment of the present application, the positive effect of controlling the concentration of the endpoint solution of the second dilution to 0.625 ng / mL to 500 ng / mL is that within this concentration range, it is possible to ensure that an accurate quantitative correction equation is obtained by plotting a standard curve graph using standards of known concentrations and internal standards, thereby accurately reflecting the content of cortisol based on the signal response degree of the urine test sample.

[0056] In some optional embodiments, the ratio of the volume of the urine sample to be tested to the volume of the cortisol isotope internal standard working solution is 1:2 to 1:6.

[0057] In the embodiment of the present application, the positive effect of controlling the volume ratio of the urine sample to be tested and the volume of the cortisol isotope internal standard working solution to be 1:2 to 1:6 is that within the range of this volume ratio, the appropriate signal response of the cortisol isotope internal standard in the cortisol isotope internal standard working solution and the cortisol in the urine sample to be tested can be ensured, thereby ensuring the accuracy of liquid chromatography tandem mass spectrometry detection, and then accurately determining the content of cortisol.

[0058] In some optional embodiments, the cortisol isotope internal standard solvent includes a mixture of methanol and water, wherein the volume ratio of the methanol to the water is 1:3 to 3:1.

[0059] In the embodiment of the present application, the positive effect of controlling the volume ratio of methanol and water to 1:3 to 3:1 is that within this range, the solute of the cortisol isotope internal standard solution can be ensured to be fully dissolved, while effectively removing a small amount of protein in the urine and reducing the background signal, thereby obtaining an internal standard solution with the expected function.

[0060] The column capacity of the solid phase extraction column used in the solid phase extraction is ≥60 mg, and the column filler is C18 or HLB.

[0061] The specific steps to make the urine sample free of cortisol are to determine whether the cortisol in the urine matrix has been completely removed by the peak at the retention time of liquid chromatography-tandem mass spectrometry. If it can still be detected, repeat the above operation with a new extraction column until the urine matrix is ​​free of cortisol.

[0062] In some optional embodiments, the sampling volume of the urine sample to be tested is 10 μL to 100 μL.

[0063] In the embodiment of the present application, the positive effect of controlling the sampling volume of the urine sample to be tested to 10 μL to 100 μL is that within the range of the sampling volume, the sampling volume of the sample can be controlled to ensure that the sample for testing is sufficient, thereby ensuring the accuracy of the test.

[0064] In some optional embodiments, the centrifugal speed is ≥12000 rpm, and the centrifugal time is 2 min to 10 min.

[0065] In the embodiments of the present application, controlling the specific parameters of centrifugation can ensure the removal of impurities in the urine sample to be tested, thereby improving the detection accuracy of subsequent liquid chromatography tandem mass spectrometry.

[0066] In some optional embodiments, the liquid chromatography tandem mass spectrometry includes a liquid chromatography, the chromatographic column of the liquid chromatography is a reverse phase chromatography column, the column temperature of the liquid chromatography is 30°C to 50°C, the injection volume of the liquid chromatography is 2 μL to 10 μL, and the flow rate of the liquid chromatography is 0.3 mL / min to 0.5 mL / min;

[0067] The liquid chromatography adopts gradient elution mode for chromatographic separation, the mobile phase A of the gradient elution comprises an aqueous solution with a mass fraction of 0% to 0.1% formic acid, and the mobile phase B of the gradient elution comprises a methanol solution with a mass fraction of 0% to 0.1% formic acid.

[0068] In the embodiments of the present application, by controlling the specific parameters of the liquid chromatography, the specific column temperature, injection volume and flow rate can be coordinated through the reverse phase chromatography column, and the mobile phase A and mobile phase B of the gradient elution can be further limited, so as to ensure that the substances in the urine test sample are separated after the liquid chromatography, thereby ensuring the accuracy of the subsequent mass spectrometry detection.

[0069] In the actual application of this method, the reverse phase chromatography column generally uses a C8 or C18 column.

[0070] In some optional embodiments, the gradient elution specifically comprises:

[0071] 0~2.80min, the volume percentage of mobile phase A is 25%~45%, and the volume percentage of mobile phase B is 55%~75%;

[0072] 2.81min, the volume percentage of mobile phase A decreased to 0-20%, and the volume percentage of mobile phase B increased to 80%-100%;

[0073] 2.81min~3.50min, the volume percentage of mobile phase A is 0~20%, and the volume percentage of mobile phase B is 80%~100%;

[0074] 3.51min, the volume percentage of mobile phase A increased by 25% to 45%, and the volume percentage of mobile phase B increased by 55% to 75%;

[0075] 3.51min~4.50min, the volume percentage of mobile phase A is 25%~45%, and the volume percentage of mobile phase B is 55%~75%.

[0076] In the examples of the present application, controlling the ratio of the mobile phase A and the mobile phase B in the specific gradient elution can ensure the complete separation of cortisol and other interfering substances.

[0077] In some optional embodiments, the liquid chromatography tandem mass spectrometry comprises a mass spectrometer;

[0078] The mass spectrometer includes an electrospray ion source, the working mode of the mass spectrometer is a negative ion mode, and the ion source parameters of the mass spectrometer include curtain gas: 30psi±5psi, collision gas: 9.0psi±0.2psi, ion source voltage: -4500V±10V, ion source temperature: 500℃±10℃, nebulizer gas: 40psi±5psi, and auxiliary heating gas: 50psi±5psi.

[0079] In some optional embodiments, the ion pairs of the mass spectrometer include: cortisol-d ion pairs: 407.2 / 331.1, 407.2 / 297.1, 407.2 / 282;

[0080] Cortisol-d and / or cortisol-13C ion pairs: determined by the isotope labeling characteristics of the cortisol isotope internal standard (for example: cortisol-13C3 ion pairs are 410.2 / 334.1, 410.2 / 300.2, 410.2 / 285.2).

[0081] In the embodiment of the present application, by controlling the specific parameters of the mass spectrometer, the content of cortisol can be specifically detected using the multiple reaction monitoring mode in the triple quadrupole. At the same time, a quantitative correction equation can be obtained by plotting a standard curve based on a calibrator solution and an internal standard of known concentration. The content of cortisol can then be accurately calculated based on the signal response of the analyte in the urine test sample, thereby achieving large-scale determination of free cortisol in urine.

[0082] By controlling the specific ion pairs of cortisol in the mass spectrometer and coordinating with the solute of the cortisol isotope internal standard solution, the cortisol content in the urine sample to be tested can be accurately determined, thereby realizing the large-scale determination of free cortisol in urine.

[0083] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are intended only to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are usually measured according to national standards. If there is no corresponding national standard, then the conditions recommended by the manufacturer are followed.

[0084] Example 1

[0085] 1. Preparation of blank urine matrix: Mix at least 100 mL of human urine sample, adsorb free cortisol in urine through solid phase extraction column HLB (3 mL / 60 mg), collect the effluent during loading as urine matrix; judge whether cortisol in urine matrix is ​​completely removed by the peak at retention time of liquid chromatography tandem mass spectrometry. If it can still be detected, repeat the above operation with a new extraction column until there is no cortisol in urine matrix, which is used as blank urine matrix. The prepared blank urine matrix is ​​used in the subsequent preparation stage.

[0086] 2. Preparation of calibration solution: Weigh 0.0100g of cortisol solid powder, dilute it to 10mL in a volumetric flask with methanol, dissolve it to obtain a cortisol mother solution with a concentration of 1.0mg / mL, and then dilute it with a mixture of methanol and water (1:1, v / v) to obtain a cortisol working solution with a concentration of 10μg / mL. Finally, dilute it step by step with the prepared blank urine matrix to obtain a cortisol calibration solution with a concentration range of 0.625ng / mL to 500ng / mL.

[0087] 3. Preparation of cortisol isotope internal standard working solution: dilute the internal standard stock solution with a mixture of methanol and water (1:1 v / v) to prepare a cortisol isotope internal standard working solution with a concentration of 5 ng / mL.

[0088] 4. Sample pretreatment: Take 50 μL of urine sample to be tested, calibration solution or quality control product respectively, mix with 200 μL of cortisol isotope internal standard working solution (1:4, v / v), vortex for 1 min to mix, centrifuge for 5 min (room temperature, 14000 rpm), take 200 μL of supernatant into the injection vial to obtain urine test sample, and then test it on the machine.

[0089] 5. Instrument conditions: Liquid chromatography conditions are as follows:

[0090] Chromatographic column: Kinetex-C18 column (100×3.0mm, 2.6μm, pore size, Phenomenex, Torrance, CA, USA);

[0091] Column temperature: 40°C;

[0092] Injection volume: 5 μL;

[0093] Flow rate: 0.4 mL / min;

[0094] Mobile phase A was formic acid in water, and mobile phase B was formic acid in methanol, and isocratic elution was used.

[0095] The liquid phase gradient of the high performance liquid chromatography-tandem mass spectrometer is:

[0096] 0-2.80min, the volume percentage of mobile phase A is 35%, and the volume percentage of mobile phase B is 65%;

[0097] 2.81min, the volume percentage of mobile phase A decreased to 0%, and the volume percentage of mobile phase B increased to 100%;

[0098] 2.81min~3.50min, the volume percentage of mobile phase A is 0%, and the volume percentage of mobile phase B is 100%;

[0099] 3.51min, the volume percentage of mobile phase A increased to 35%, and the volume percentage of mobile phase B increased to 65%;

[0100] 3.51min~4.50min, the volume percentage of mobile phase A is 35%, and the volume percentage of mobile phase B is 65%.

[0101] Under this gradient elution condition, the retention time of the analyte is about 2.25 min (e.g. Figure 3 and Figure 4 As shown in Figure 2, the internal standard retention time is about 2.27 min. This shows that the liquid chromatography detection time in the present application method is short, the peak time is fast and the detection throughput is high.

[0102] 6. Instrument conditions: Mass spectrometry conditions are as follows:

[0103] An AB Sciex 5500 triple quadrupole mass spectrometer was used; an electrospray ion source, negative ion mode, multiple reaction monitoring mode (MRM), and MRM scan mode were used. The specific mass spectrometry parameters are shown in Table 1; the ion source parameters included: curtain gas: 30 psi, collision gas: 9 psi, ion source voltage: -4500 V, ion source temperature: 500°C, nebulizer gas 40 psi, and auxiliary heating gas: 50 psi.

[0104] Table 1 Mass spectrometry parameters

[0105] Analyte name MRM ion pairs DP(V) EP(V) CE(V) CXP(V) Cortisol Quantitation Ion Pair 407.2 / 297.1 -96 -10 -44 -22 Cortisol Qualifier Pair 407.2 / 282.1 -71 -10 -53 -22 Cortisol-13C3 Quantitative Ion Pair 410.2 / 300.2 -92 -10 -45 -18 Cortisol-13C3 Qualifier 410.2 / 285.2 -68 -10 -53 -18

[0106] 7. Verify the above methods and parameters. The specific verification parameters and verification results are as follows:

[0107] (1) Linear range:

[0108] Each concentration of the calibrator used to draw the standard curve was tested 6 times, and the average value, CV and recovery rate of each concentration sample were calculated. The results are shown in Table 2.

[0109] Table 2 Average values, CV and recovery rates of each concentration linear range

[0110]

[0111] From the data in Table 2, we can see that the linear range of urinary cortisol is 0.625 ng / mL to 500 ng / mL, and the linear correlation coefficient of the goodness of fit of the six curves is R 2 =0.9998, indicating that the linearity of the curve fits the measured value very well and meets the needs of clinical sample testing.

[0112] (2) Precision:

[0113] Precision evaluation included intra-batch precision and inter-batch precision evaluation. Self-made quality control samples with three concentration levels (4 ng / mL, 25 ng / mL, and 200 ng / mL) were used. Each sample was measured six times to obtain the intra-batch precision, and the inter-batch precision was obtained by continuous measurement for six days. The results are shown in Table 3.

[0114] Table 3 Intra-batch and inter-batch precision experimental data of cortisol in urine

[0115]

[0116] As shown in Table 3, the precision investigation results show that the intra-batch precision of cortisol is ≤2.98%, and the inter-batch precision is ≤2.97%, which has very good precision and meets the requirements of quantitative analysis.

[0117] (3) Accuracy:

[0118] The recovery experiment was used to evaluate the accuracy: four different concentrations of the analyte were added to a patient sample at a ratio of 9:1 (v / v), and the final concentration after spiking was required to cover the entire medical decision level; an equal volume of solvent was added to another patient sample, and the two samples were measured repeatedly 6 times to calculate the recovery rate. The recovery rate was calculated using the formula: Recovery rate (%) = (measured concentration - basic concentration) / spiked theoretical concentration * 100%; the results are shown in Table 4.

[0119] Table 4 Cortisol recovery rate experimental data table

[0120]

[0121] From the data in Table 4, it can be seen that the spiked recoveries of cortisol in urine are all between 93.3% and 109%, which meets the requirement of a recovery rate between 85% and 115%, indicating that the results meet the requirements of quantitative analysis.

[0122] (4) Analytical sensitivity:

[0123] The limit of detection (LOD) is defined as the minimum detectable concentration (S / N>3); the analytical sensitivity, also known as the limit of quantification (LOQ), is defined as the lowest concentration of the analyte that can be reliably quantified, requiring S / N>10, coefficient of variation CV<20%, and the bias between the theoretical value and the measured value not exceeding 20%. The results are shown in Table 5.

[0124] Table 5 Experimental data of limit of quantitation and limit of detection

[0125]

[0126]

[0127] As shown in Table 5, the quantitative limit of this method is 0.125 ng / mL, which means that the lower limit of quantification is low and can meet the needs of clinical testing.

[0128] (5) Matrix effect:

[0129] The post-column infusion method was used: the analyte standard solution (10 μg / mL) was injected from the mass spectrometer at a flow rate of 10 μL / min, and the pure matrix was prepared and injected from the liquid phase under running conditions to observe whether there was a matrix effect.

[0130] The results are as follows Figure 5 As shown, the retention time of cortisol is 2.25 min, and there is no matrix enhancement or attenuation effect at this retention time.

[0131] Example 2

[0132] Comparing Example 2 with Example 1, the difference between Example 2 and Example 1 is:

[0133] The steps and required sample amounts for processing samples by the method disclosed in Example 1, the liquid-liquid extraction method used in conventional liquid chromatography tandem mass spectrometry, and the solid phase extraction method used in conventional liquid chromatography tandem mass spectrometry are specifically shown in Table 6.

[0134] Table 6 Differences in the steps and sample amounts required for each method

[0135]

[0136]

[0137] Taking the processing of 1000 samples as an example, the differences between liquid-liquid extraction and solid phase extraction and the method described in Example 1 in terms of pre-processing time, reagent and consumable costs, etc. are analyzed. The results are shown in Table 7.

[0138] Table 7 Comparison of sample pretreatments of direct mixing and dilution method, liquid-liquid extraction and solid phase extraction in Example 1

[0139] Comparison parameters Liquid-Liquid Extraction Steps Solid Phase Extraction Steps Direct Mixing Dilution Method Pre-processing time (96 samples) 60min 120min 10min Reagent cost / yuan (1000 samples) 4000 4000 2000 Consumables cost / yuan (1000 samples) 3000 32000 1000

[0140] It can be seen from Tables 6 and 7 that compared with liquid-liquid extraction and solid phase extraction, the direct mixing and dilution method not only requires a smaller sample size, fewer total operation steps, shorter pretreatment time, and lower consumables costs, but also uses fewer steps of organic solvents in the entire process, resulting in less environmental pollution. It has significant advantages in being promoted and applied in clinical laboratory testing, and can be used on a large scale for the detection of free cortisol in urine.

[0141] One or more technical solutions in the embodiments of the present application also have at least the following technical effects or advantages:

[0142] (1) The method for detecting free cortisol in urine by using liquid chromatography-tandem mass spectrometry provided in the embodiment of the present application is different from the traditional liquid chromatography-tandem mass spectrometry detection of cortisol. It only requires adding a cortisol isotope internal standard working solution to the urine sample to be tested, and then centrifuging the sample. This makes the sample pretreatment simple and rapid, requires less sample volume, and has low reagent and consumable costs. Therefore, this method can realize large-scale liquid chromatography-tandem mass spectrometry detection of free cortisol in urine.

[0143] (2) The present application provides a method for detecting free cortisol in urine using liquid chromatography-tandem mass spectrometry. The method only requires adding a specific cortisol isotope internal standard working solution (especially an internal standard solution with a methanol-water mixture as a solvent) to the urine sample, mixing and centrifuging the sample before directly performing analysis on the machine. There is no need to pre-treat the sample by liquid-liquid extraction or solid-phase extraction.

[0144] (3) The method provided in the embodiment of the present application for detecting free cortisol in urine by using liquid chromatography tandem mass spectrometry can detect free cortisol in urine within 13 minutes (including the analysis time) under the premise that the precision, accuracy, linear range, analytical sensitivity and matrix effect all meet the requirements of clinical application. Compared with the prior art, not only is the sample processing step simple, the time is short, the cost is low and the environmental pollution is small, but the sample size is also small.

[0145] (4) The embodiment of the present application provides a method for detecting free cortisol in urine using liquid chromatography-tandem mass spectrometry. The standard curve drawn by using the prepared blank urine matrix to prepare the standard product can better reflect the actual concentration of human samples. All of these are conducive to the promotion and application of this method to the high-throughput and accurate detection of free cortisol in urine in clinical laboratories.

[0146] Various embodiments of the present application may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present application; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values ​​within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.

[0147] In the present application, in the absence of any contrary description, the directional words used, such as "upper" and "lower", are specifically the directions of the drawings in the accompanying drawings. In addition, in the description of the present specification, the terms "including", "comprising", etc. refer to "including but not limited to". In this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that there is any such actual relationship or order between these entities or operations. In this article, "and / or" describes the association relationship of the associated objects, indicating that there may be three relationships, for example, A and / or B, which can represent: A exists alone, A and B exist at the same time, and B exists alone. Wherein A, B can be singular or plural. In this article, "at least one" refers to one or more, and "plural" refers to two or more. "At least one", "at least one of the following" or similar expressions refer to any combination of these items, including any combination of singular or plural items. For example, "at least one of a, b, or c", or "at least one of a, b and c", can both mean: a, b, c, ab (i.e. a and b), ac, bc or abc, where a, b, c can be single or plural, respectively.

[0148] The above description is only a specific implementation of the present application, so that those skilled in the art can understand or implement the present application. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to the embodiments shown herein, but will conform to the widest range consistent with the principles and novel features applied for herein.

Claims

1. A method for detecting free cortisol in urine using liquid chromatography tandem mass spectrometry, characterized in that: The method comprises: mixing a calibration solution and a urine sample to be tested with a cortisol isotope internal standard working solution respectively, then centrifuging, taking the supernatant, and obtaining a calibration supernatant and a sample supernatant respectively; The supernatant of the calibration product is detected by liquid chromatography-tandem mass spectrometry, and a standard curve is drawn; Using liquid chromatography tandem mass spectrometry to detect the supernatant of the sample to be tested, and obtaining the content of free cortisol in the urine sample to be tested according to the standard curve; Wherein, the cortisol isotope internal standard working solution comprises a cortisol isotope internal standard solute and a cortisol isotope internal standard solvent; The cortisol isotope internal standard solute includes cortisol-d m and / or cortisol-13C; wherein the cortisol isotope internal standard solute includes cortisol-d m In the case of , m ≥ 3; The cortisol isotope internal standard solvent includes methanol and / or water; The conditions of liquid chromatography in the liquid chromatography tandem mass spectrometry are as follows: Chromatographic column: Kinetex-C18 chromatographic column; the specifications of the Kinetex-C18 chromatographic column meet the following requirements: 100×3.0mm, 2.6µm, 100Åpore size, Phenomenex, Torrance, CA, USA; column temperature: 40°C; injection volume: 5μL; flow rate: 0.4mL / min; mobile phase A is a formic acid aqueous solution with a mass fraction of 0% to 0.1%, and mobile phase B is a formic acid methanol solution with a mass fraction of 0% to 0.1%; The liquid chromatography in the liquid chromatography tandem mass spectrometry uses a gradient elution mode for chromatographic separation, and the gradient elution is: 0 to 2.80 min, the volume percentage of mobile phase A is 35%, and the volume percentage of mobile phase B is 65%; 2.81min, the volume percentage of mobile phase A decreased to 0%, and the volume percentage of mobile phase B increased to 100%; 2.81min~3.50min, the volume percentage of mobile phase A is 0%, and the volume percentage of mobile phase B is 100%; 3.51min, the volume percentage of mobile phase A increased to 35%, and the volume percentage of mobile phase B increased to 65%; 3.51min~4.50min, the volume percentage of mobile phase A is 35%, and the volume percentage of mobile phase B is 65%.

2. The method according to claim 1, characterized in that The method further comprises: The ex vivo urine samples were subjected to solid phase extraction until cortisol was free to obtain blank urine matrix; Prepare the stock solution of cortisol and make the first dilution, then make the second dilution with blank urine matrix to obtain the calibration solution Wherein, the concentration of the calibration solution is 0.625ng / mL to 500ng / mL.

3. The method according to claim 2, characterized in that The dilution solvent of the first dilution is a mixture of methanol and water, wherein the volume ratio of the methanol to the water is 1:3 to 3:

1.

4. The method according to claim 2, characterized in that: The second dilution includes performing the second dilution in a stepwise dilution manner, and the endpoint solution concentration of the second dilution is 0.625 ng / mL to 500 ng / mL.

5. The method according to claim 1, characterized in that The ratio of the volume of the urine sample to be tested to the volume of the cortisol isotope internal standard working solution is 1:2 to 1:

6.

6. The method according to claim 1, characterized in that The cortisol isotope internal standard solvent includes a mixture of methanol and water, wherein the volume ratio of the methanol to the water is 1:3 to 3:

1.

7. The method according to claim 1, characterized in that The sampling volume of the urine sample to be tested is 10 μL to 100 μL.

8. The method according to claim 1, characterized in that The centrifugal speed is ≥12000 rpm, and the centrifugal time is 2 min to 10 min.

9. The method according to claim 1, characterized in that: The liquid chromatography tandem mass spectrometry comprises a mass spectrometer; The mass spectrometer includes an electrospray ion source, the working mode of the mass spectrometer is a negative ion mode, and the ion source parameters of the mass spectrometer include curtain gas: 30psi±5psi, collision gas: 9.0psi±0.2psi, ion source voltage: -4500V±10V, ion source temperature: 500℃±10℃, nebulizer gas: 40psi±5psi, and auxiliary heating gas: 50psi±5psi.